Unlock the value of a complete solution for viral vector production

by John Sotirakos | February 5, 2024

9e2ec6bc-b475-4866-bc14-1164938e2865
Realizing the full potential of gene therapy requires an efficient viral vector manufacturing process. This imperative is complicated by the fact that unlike traditional biologics, gene therapies do not have existing process templates to guide development. For many companies developing these next generation modalities, the required breadth of expertise, capabilities, and capacity is not available in-house to establish a robust, high yield, and scalable process. This necessitates selection of a partner with the ability to fill these gaps.

A partner that offers a fully integrated solution for viral vector production offers significant advantages compared to a patchwork of multiple suppliers, each focused on a separate unit operation:

·         An integrated solution leverages a comprehensive suite of advanced technologies and expertise to facilitate and accelerate the journey to market.

·         A partner with a holistic view can offer valuable insight into solutions and technologies that improve both upstream vector production and reduce loss of viral vectors during downstream purification.

·         A holistic approach focuses on establishing a reliable, sustainable, and cost-effective process that will keep pace with demand as it evolves over time.

·         Leveraging the experience of a knowledgeable partner can help prevent costly surprises later by more effective planning for manufacturing.

Learn more about how an integrated solutions partner for viral vector production can deliver significant advantages for your gene therapy programs.

Click here!

Senior Marketing Communications Manager, Cell & Gene Therapy - BioProcessing

Related Posts

Starting your journey into manufacturing – choosing a cell line development provider

One of the biggest decisions which any company developing biological medicines makes is to move forward to the manufacture of their product. …

GEN Regulatory Podcast link LIVE!

The success of cell and gene therapy products in recent years to treat a host of complex diseases…

Assembling a new gene therapy company to develop the next generation of pioneering medicines

Having both recently graduated from our Masters degrees, Christina in Neuroscience from ETH Zürich and Charlotte in Chemistry…

Webinar: Developing A Scalable Upstream Bioreactor Process for Lentiviral Vector Production in Suspension

Gene therapies hold the promise to change lives. As your path to patients accelerates, how can you assure…

Scroll to Top